First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

The development of antiangiogenic treatments, followed by immune checkpoint inhibitors (ICI), has significantly changed the management of metastatic clear cell renal cell cancer. Several phase III trials show the superiority of combination therapy, dual immunotherapy (ICI-ICI) or ICI plus tyrosine k...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, Slimane Dermeche, Jean-Christophe Eymard, Sabrina Falkowski, Marine Gross-Goupil, Gabriel Malouf, Bérangère Narciso, Christophe Sajous, Sophie Tartas, Eric Voog, Alain Ravaud
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	metastatic clear cell renal cell carcinoma first-line treatment immunotherapy tyrosine kinase inhibitors combinations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/becd57d4d59b43458af2ace5bd8612ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:becd57d4d59b43458af2ace5bd8612ce
record_format	dspace
spelling	oai:doaj.org-article:becd57d4d59b43458af2ace5bd8612ce2021-11-11T15:34:33ZFirst-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?10.3390/cancers132155482072-6694https://doaj.org/article/becd57d4d59b43458af2ace5bd8612ce2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5548https://doaj.org/toc/2072-6694The development of antiangiogenic treatments, followed by immune checkpoint inhibitors (ICI), has significantly changed the management of metastatic clear cell renal cell cancer. Several phase III trials show the superiority of combination therapy, dual immunotherapy (ICI-ICI) or ICI plus tyrosine kinase inhibitors (TKI) of the vascular endothelium growth factor (VEGF) over sunitinib monotherapy. The question is therefore what is the best combination for a given patient? A strategy based on the International Metastatic Database Consortium (IMDC) classification is currently recommended with pembrolizumab + axitinib, cabozantinib + nivolumab, and lenvatinib + pembrolizumab (for all patients) or nivolumab + ipilimumab (for patients with intermediate or poor risk), which are the first-line treatment standards of care. However, several issues remain unresolved and require further investigation, such as the PD-L1 status, the relevance of possible options based on the patient’s profile, and consideration of second-line and subsequent treatments.Yann-Alexandre VanoSylvain LadoireRéza ElaidiSlimane DermecheJean-Christophe EymardSabrina FalkowskiMarine Gross-GoupilGabriel MaloufBérangère NarcisoChristophe SajousSophie TartasEric VoogAlain RavaudMDPI AGarticlemetastatic clear cell renal cell carcinomafirst-line treatmentimmunotherapytyrosine kinase inhibitorscombinationsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5548, p 5548 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metastatic clear cell renal cell carcinoma first-line treatment immunotherapy tyrosine kinase inhibitors combinations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	metastatic clear cell renal cell carcinoma first-line treatment immunotherapy tyrosine kinase inhibitors combinations Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yann-Alexandre Vano Sylvain Ladoire Réza Elaidi Slimane Dermeche Jean-Christophe Eymard Sabrina Falkowski Marine Gross-Goupil Gabriel Malouf Bérangère Narciso Christophe Sajous Sophie Tartas Eric Voog Alain Ravaud First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
description	The development of antiangiogenic treatments, followed by immune checkpoint inhibitors (ICI), has significantly changed the management of metastatic clear cell renal cell cancer. Several phase III trials show the superiority of combination therapy, dual immunotherapy (ICI-ICI) or ICI plus tyrosine kinase inhibitors (TKI) of the vascular endothelium growth factor (VEGF) over sunitinib monotherapy. The question is therefore what is the best combination for a given patient? A strategy based on the International Metastatic Database Consortium (IMDC) classification is currently recommended with pembrolizumab + axitinib, cabozantinib + nivolumab, and lenvatinib + pembrolizumab (for all patients) or nivolumab + ipilimumab (for patients with intermediate or poor risk), which are the first-line treatment standards of care. However, several issues remain unresolved and require further investigation, such as the PD-L1 status, the relevance of possible options based on the patient’s profile, and consideration of second-line and subsequent treatments.
format	article
author	Yann-Alexandre Vano Sylvain Ladoire Réza Elaidi Slimane Dermeche Jean-Christophe Eymard Sabrina Falkowski Marine Gross-Goupil Gabriel Malouf Bérangère Narciso Christophe Sajous Sophie Tartas Eric Voog Alain Ravaud
author_facet	Yann-Alexandre Vano Sylvain Ladoire Réza Elaidi Slimane Dermeche Jean-Christophe Eymard Sabrina Falkowski Marine Gross-Goupil Gabriel Malouf Bérangère Narciso Christophe Sajous Sophie Tartas Eric Voog Alain Ravaud
author_sort	Yann-Alexandre Vano
title	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
title_short	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
title_full	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
title_fullStr	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
title_full_unstemmed	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
title_sort	first-line treatment of metastatic clear cell renal cell carcinoma: what are the most appropriate combination therapies?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/becd57d4d59b43458af2ace5bd8612ce
work_keys_str_mv	AT yannalexandrevano firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT sylvainladoire firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT rezaelaidi firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT slimanedermeche firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT jeanchristopheeymard firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT sabrinafalkowski firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT marinegrossgoupil firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT gabrielmalouf firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT berangerenarciso firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT christophesajous firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT sophietartas firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT ericvoog firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies AT alainravaud firstlinetreatmentofmetastaticclearcellrenalcellcarcinomawhatarethemostappropriatecombinationtherapies
_version_	1718435208019050496

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

Ejemplares similares